Septerna (NASDAQ:SEPN) Releases Earnings Results, Beats Expectations By $0.05 EPS

Septerna (NASDAQ:SEPN) announced its quarterly earnings data on Thursday. The company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.05, Zacks reports. The business had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.13 million.

Septerna Trading Down 3.0 %

Shares of NASDAQ SEPN opened at $6.10 on Friday. Septerna has a twelve month low of $4.17 and a twelve month high of $28.99. The stock’s fifty day moving average price is $9.96.

Insider Activity at Septerna

In other news, CFO Gil M. Labrucherie purchased 6,282 shares of the business’s stock in a transaction dated Tuesday, February 25th. The shares were bought at an average cost of $5.59 per share, for a total transaction of $35,116.38. Following the completion of the acquisition, the chief financial officer now directly owns 36,282 shares in the company, valued at approximately $202,816.38. This trade represents a 20.94 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Alan Ezekowitz acquired 41,355 shares of Septerna stock in a transaction dated Thursday, March 6th. The shares were purchased at an average cost of $6.00 per share, with a total value of $248,130.00. Following the completion of the transaction, the director now directly owns 104,101 shares of the company’s stock, valued at $624,606. This trade represents a 65.91 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 74,346 shares of company stock worth $439,670 in the last quarter.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Wells Fargo & Company reduced their price target on Septerna from $14.00 to $11.00 and set an “equal weight” rating on the stock in a research report on Friday. Cantor Fitzgerald restated an “overweight” rating and set a $50.00 target price on shares of Septerna in a report on Tuesday, February 11th.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.